KW
Kim, Woonghee
20 yayın · 222 atıf · 2021–2025
Yayın
20
Atıf
222
Yıllar
5
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Anticancer effects and mechanisms of Pulsatilla chinensis, Bupleurum chinense and Polyporus umbellatus on human lung carcinoma and hepatoma cells
|
2025 | Article | 0 |
|
Synthesis and biological assessment of BUB1B inhibitors for the treatment of clear cell renal cell carcinoma
|
2025 | Article | 3 |
|
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in rats
|
2025 | Article | 4 |
|
Identification of <i>SPP1</i><SUP>+</SUP> macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics
|
2024 | Article | 7 |
|
Unveiling the Molecular Mechanisms of Glioblastoma through an Integrated Network-Based Approach
|
2024 | Article | 7 |
|
Discovery of Cell-Permeable Allosteric Inhibitors of Liver Pyruvate Kinase: Design and Synthesis of Sulfone-Based Urolithins
|
2024 | Article | 2 |
|
Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma
|
2024 | Article | 3 |
|
Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning ( vol 83 , 104214 , 2022)
|
2024 | Correction | 0 |
|
Synthesis, spectroscopic characterization, DFT and molecular docking of N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl) naphthalene-1-sulfonamide derivatives
|
2024 | Article | 2 |
|
Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
|
2024 | Article | 3 |
|
Open MoA: revealing the mechanism of action (MoA) based on network topology and hierarchy
|
2023 | Article | 5 |
|
Characterization of an <i>in vitro</i> steatosis model simulating activated <i>de novo</i> lipogenesis in MAFLD patients
|
2023 | Article | 9 |
|
Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients
|
2023 | Article | 11 |
|
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
|
2023 | Article | 11 |
|
Discovery of therapeutic agents targeting <i>PKLR </i>for <i>NAFLD </i>using drug repositioning
|
2022 | Article | 22 |
|
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach
|
2022 | Article | 25 |
|
A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
|
2022 | Article | 17 |
|
Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning
|
2021 | Article | 14 |
|
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
|
2021 | Article | 64 |
|
Discovery of Functional Alternatively Spliced <i>PKM</i> Transcripts in Human Cancers
|
2021 | Article | 13 |